Allez Health (formerly known as Zense-Life), an emerging biosensor venture founded by proven experts in the continuous glucose monitoring (CGM) space, announced a $60 million Series A+ financing. This funding round was led by Korean in-vitro diagnostics company Osang Healthcare Co., Ltd. as a strategic investor, with participation from existing investors. The new funding round is expected to be used to accelerate growth toward pivotal trials, support regulatory approval filings, and scale manufacturing operations.
Allez Health is a CGM biosensor platform with novel sensor technology that is intended to transform cost barrier while enhancing performance and user experience. And since its founding, Allez Health has accomplished several significant milestones, including seven issued patents and over 40 pending patent applications, over 80 clinical studies aggregating more than 1,500 users, and a pivotal study in 120 insulin users.
After completing a pivotal study and having secured key strategic investment and select distribution and manufacturing arrangements, Allez Health expects to accelerate its progress toward commercialization in multiple global markets, assuming the timely receipt of the necessary regulatory approvals and the continued availability of capital.
KEY QUOTES:
“We believe that person-centric health is critical for optimal health solutions. We aim to bring to market a sensor that combines access, affordability, and reliable performance, because when it comes to an individual’s health, no one should have to choose between price and performance.”
- Leif Bowman, co-founder and CEO at Allez Health
“Since the founding of Allez Health, we have been impressed by their progress and are excited to officially forge a strong collaboration with them. Their innovative design and technical advances, coupled with Osang’s world-class manufacturing capability and global reach, will bring meaningful access to world-class CGM technology for millions of people with diabetes as well as the broader wellness market.”
- Dr. Chulhun Kang, CEO of Osang Healthcare
